Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Valeo Pharma To Launch Enoxaparin In Canada Early Next Year

Licensing Agreement Signed With Techdow Last Year

Executive Summary

Canadian firm Valeo Pharma is looking to make a splash with enoxaparin biosimilars, Redesca and Redesca HP, following approval from Health Canada.

You may also be interested in...



Valeo Chalks Up Another Milestone For Canadian Enoxaparin Biosimilars

Canada’s Valeo Pharma insists it has “worked tirelessly to ensure a robust supply of Redesca,” after completing another milestone for the company’s enoxaparin biosimilar product.

Quebec To List Enoxaparin Biosimilar As Valeo Pharma Prepares Launch

Canada’s Valeo Pharma says it intends to pursue discussions for the inclusion of its Redesca enoxaparin biosimilar on all other provincial formularies, after being backed for listing on the Quebec public health plan.

Sandoz Canada Joins Humira Biosimilar Race With Hyrimoz Approval

Sandoz Canada is looking to roll out its biosimilar to AbbVie’s Humira early in the new year following approval from Health Canada, with multiple other adalimumab candidates also reportedly approved.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB150524

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel